Get started
Work

Serious infection risk of certolizumab compared with other systemic therapies in women with psoriasis

Year: 2026
Type: article
Study design: Observational Study
Abstract: In this cohort study of 11 034 treatment episodes from the BADBIR register, we evaluated the risk of serious infection associated with certolizumab compared with other systemic treatments in women with psoriasis aged ≤ 50 years. After inverse probability weighting and recurrent event modelling, certolizumab was associated with a higher risk of serious infection compared with adalimumab and ustekinumab. Although residual confounding by indication and slight age imbalance cannot be excluded, these findings suggest a modestly increased infection risk with certolizumab in this population.
DOI: 10.1093/bjd/ljag170
Authors: Heber Rew Bright Bright, Catherine H Smith, Philip Laws, Nick J Reynolds, Olivia Hughes, Duc Binh Phan, Mark Lunt, Richard B Warren, Zenas Z N Yiu
Institutions: Manchester Academic Health Science Centre, University of Manchester, NIHR Manchester Biomedical Research Centre, Northern Care Alliance NHS Foundation Trust, King's College London, Guy's and St Thomas' NHS Foundation Trust, University of Leeds, Chapel Allerton Hospital, NIHR Newcastle Biomedical Research Centre, Newcastle University, Cardiff University
Language: English
Subfield: Immunology
Open Access status: green
OpenAlex ID: W7158485629
FWCI:
Cites:
Cited by:
Related to: